Eye-Opening FDA Strategies to Ensure Global Drug Safety
The FDA Town Hall at the 2024 DIA Europe Conference provided an insightful overview of the FDA’s strategic initiatives...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Authority FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
The FDA Town Hall at the 2024 DIA Europe Conference provided an insightful overview of the FDA’s strategic initiatives...
Be Biopharma, Inc., a pioneer in developing Engineered B Cell Medicines (BCMs), has received IND clearance from the FDA...
A study published in BMC Veterinary Research demonstrates the effectiveness of OKV-119, a miniature drug implant containing exenatide, in...
The Precision Cancer Consortium (PCC) and Massive Bio have conducted a comprehensive study on the efficacy of Massive Bio’s...
KEYTRUDA (pembrolizumab) has demonstrated promising results in the treatment of high-risk early-stage triple-negative breast cancer (TNBC) in the Phase...
AstraZeneca and Alexion will present at the International Symposium on Amyloidosis (ISA) 2024, showcasing studies on their amyloidosis treatment...
Tennessee Cancer Specialists (TCS), an East Tennessee oncology group, has partnered with Sarah Cannon Research Institute (SCRI), a leading...
SpyBiotech and The University of Oxford have entered a research agreement to develop a vaccine against Epstein-Barr virus (EBV)....
Fulgent Pharma, a subsidiary of Fulgent Genetics, will present Phase 1 clinical data on FID-007, its lead therapeutic candidate...
The Middle East Town Hall at DIA Europe 2024 showcased significant Middle East clinical trial regulatory advancements across the...